Mentice

Mentice Operating Cash Flow

The Operating Cash Flow of Mentice (MNTC.ST) as of Nov 19, 2026 is -20.30 M SEK. In the previous year, Operating Cash Flow was 17.92 M SEK — a change of -213.28% (lower).

Operating Cash Flow

-20.30 MSEK

YoY

-213.28%

Last updated:

Operating Cash Flow of Mentice is 2025 -20.30 M SEK. Operating Cash Flow of Mentice was 2024 17.92 M SEK. It decreases by -213.28% lower compared to the previous year.

The Mentice Operating Cash Flow history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Operating Cash Flow
Date
Operating Cash Flow
Jan 1, 2018
16.01 M SEK
Jan 1, 2019
-37.28 M SEK
Jan 1, 2020
30.53 M SEK
Jan 1, 2021
-5.13 M SEK
Jan 1, 2022
14.91 M SEK
Jan 1, 2023
36.52 M SEK
Jan 1, 2024
17.92 M SEK
Jan 1, 2025
-20.30 M SEK
The Mentice Operating Cash Flow history
YEAROperating Cash FlowYoY
-20.30 MSEK-213.28%
17.92 MSEK-50.93%
36.52 MSEK+144.95%
14.91 MSEK-390.60%
-5.13 MSEK-116.80%
30.53 MSEK-181.90%
-37.28 MSEK-332.94%
16.01 MSEK+1.74%
15.73 MSEK—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Mentice Stock analysis

What does Mentice do? Mentice AB provides software and hardware simulation solutions for endovascular therapies, targeting healthcare professionals and the medical device industry. The company's solutions are scientifically validated and designed to help users acquire, retain, and enhance procedural skills in neurovascular, cardiovascular, and peripheral interventions. Mentice AB generates revenue through the sale of its simulation products and related services, with key buyers including healthcare providers and medical device manufacturers. The company operates globally, serving clients across multiple healthcare segments that require advanced training tools for minimally invasive procedures. Mentice AB's business model focuses on delivering scientifically validated simulation tools that address skill development needs in complex medical procedures. The firm's product offerings cater to both healthcare institutions seeking to train staff and medical device companies requiring validation tools for their products. By specializing in endovascular therapy simulations, Mentice AB serves a niche market with high demand for precise procedural training solutions. The company's global presence allows it to reach clients in various regions seeking advanced medical simulation technology. The company's revenue streams come from the sale of simulation software and hardware systems alongside ongoing service contracts. Healthcare providers purchase these solutions to improve staff competency in endovascular procedures, while medical device manufacturers use them to validate device performance in simulated environments. Mentice AB's solutions are specifically developed for the medical device industry and healthcare providers, creating a dual revenue stream from both sectors. The firm's focus on scientifically validated tools ensures strong market positioning within specialized medical training segments. Mentice is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Mentice stock

Operating Cash Flow of Mentice is -20.30 M SEK in 2025.

Operating Cash Flow of Mentice changed from 17.92 M SEK to -20.30 M SEK, representing a -213.28% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Operating Cash Flow Mentice since 2006 – with annual values, charts, and detailed analysis.

Operating cash flow measures the cash generated from core business operations. It is a pure measure of a company's ability to generate cash.

Operating Cash Flow's SEK is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Operating Cash Flow's Mentice historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Mentice

All Key Metrics — Mentice